Reports of Biochemistry
and Molecular Biology
Sun, Dec 22, 2024
[Archive]
Volume 11, Issue 3 (Vol.11 No.3 Oct 2022)
rbmb.net 2022, 11(3): 465-470 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Miresmaeili Mazrakhondi S A, Zare-Zardini H. Comparison of Serum Changes of Interleukin-17A and Interleukin-21 Between Schizophrenic Patients and Healthy Individuals. rbmb.net 2022; 11 (3) :465-470
URL: http://rbmb.net/article-1-939-en.html
URL: http://rbmb.net/article-1-939-en.html
Department of Biology, Faculty of Basic Science, Yazd University, Yazd, Iran.
Abstract: (1605 Views)
Background: Immunological alterations in schizophrenic patients have been considered during last decade. There are no remarkable reports on the changes of IL-17A and IL-21 in schizophrenic patients. Therefore, the purpose of this study was to evaluate changes of serum IL-17A and IL-21 in schizophrenic patients in comparison with healthy controls.
Methods: In the present study serum levels of IL-17A and IL-21 in 30 patients with schizophrenia before treatment and three months after treatment were measured by enzyme-linked immunosorbent assay (ELISA) and compare to 30 match healthy control group.
Results: Serum levels of IL-21 in schizophrenic patient was significantly higher than control group (P= 0.001). Serum levels of IL-17A in the schizophrenic patients had no significant changes than the control group (P= 0.4). Serum levels of IL-17A in patients with schizophrenia three months after treatment than before treatment had no significant change (P=0.7) and IL-21 serum levels in schizophrenic patient three month after treatment was not significant changed in comparison with this group before treatment (P= 0.06).
Conclusions: The serum levels of interlukine-21 is elevated in schizophrenic. Results of this study showed that IL-21 might be involved in the pathologic mechanism of schizophrenia.
Methods: In the present study serum levels of IL-17A and IL-21 in 30 patients with schizophrenia before treatment and three months after treatment were measured by enzyme-linked immunosorbent assay (ELISA) and compare to 30 match healthy control group.
Results: Serum levels of IL-21 in schizophrenic patient was significantly higher than control group (P= 0.001). Serum levels of IL-17A in the schizophrenic patients had no significant changes than the control group (P= 0.4). Serum levels of IL-17A in patients with schizophrenia three months after treatment than before treatment had no significant change (P=0.7) and IL-21 serum levels in schizophrenic patient three month after treatment was not significant changed in comparison with this group before treatment (P= 0.06).
Conclusions: The serum levels of interlukine-21 is elevated in schizophrenic. Results of this study showed that IL-21 might be involved in the pathologic mechanism of schizophrenia.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2022/05/10 | Accepted: 2022/05/15 | Published: 2022/12/31
Received: 2022/05/10 | Accepted: 2022/05/15 | Published: 2022/12/31
References
1. Müller N, Schwarz MJ. Cytokines, immunity and schizophrenia with emphasis on underlying neurochemical mechanisms. In: Siegel A, Zalcman SS (eds) The neuroimmunological basis of behavior and mental disorders. New York, NY: Springer, 2009;307-325. [DOI:10.1007/978-0-387-84851-8_15] [PMCID]
2. Kim YK, Kim L, Lee MS. Relationships between interleukins, neurotransmitters and psychopathology in drug-free male schizophrenics. Schizophr Res. 2000;44(3):165-75. [DOI:10.1016/S0920-9964(99)00171-1] [PMID]
3. Brown AS, Begg MD, Gravenstein S, Schaefer CA, Wyatt RJ, Bresnahan M, et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry. 2004;61(8):774-80. [DOI:10.1001/archpsyc.61.8.774] [PMID]
4. Buka SL, Tsuang MT, Torrey EF, Klebanoff MA, Bernstein D, Yolken RH. Maternal infections and subsequent psychosis among offspring. Arch Gen Psychiatry. 2001;58(11):1032-7. [DOI:10.1001/archpsyc.58.11.1032] [PMID]
5. Koponen H, Rantakallio P, Veijola J, Jones P, Jokelainen J, Isohanni M. Childhood central nervous system infections and risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2004;254(1):9-13. [DOI:10.1007/s00406-004-0485-2] [PMID]
6. Bechter K, Schreiner V, Herzog S, Breitinger N, Wollinsky KH, Brinkmeier H, et al. Cerebrospinal fluid filtration as experimental therapy in therapy refractory psychoses in Borna disease virus seropositive patients. Therapeutic effects, findings. Psychiatr Prax. 2003;30:216-20.
7. Smyth AM, Lawrie SM. The neuroimmunology of schizophrenia. Clin Psychopharmacol Neurosci. 2013;11(3):107-17. [DOI:10.9758/cpn.2013.11.3.107] [PMID] [PMCID]
8. Freidin M, Bennett MV, Kessler JA. Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc Natl Acad Sci USA. 1992;89(21):10440-3. [DOI:10.1073/pnas.89.21.10440] [PMID] [PMCID]
9. Al-Rawi KF, Ali HH, Guma MA, Mohammed Aldahham BJ, Tuleab Alaaraji SF, et al. Relationship Between IL-2, IL-17 Concentrations, and Serum Creatinine Levels in Men with Chronic Kidney Diseases. Rep Biochem Mol Biol. 2022;10(4):664-674. [DOI:10.52547/rbmb.10.4.664] [PMID] [PMCID]
10. Bahrami M, Ghazavi A, Ganji A, Mosayebi G. Anti-Inflammatory Activity of S. Marianum and N. Sativa Extracts on Macrophages. Rep Biochem Mol Biol. 2021;10(2):288-301. [DOI:10.52547/rbmb.10.2.288] [PMID] [PMCID]
11. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929-39. [DOI:10.1002/art.27334] [PMID]
12. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. [DOI:10.1126/scitranslmed.3001107] [PMID]
13. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol. 2008;26:57-79. [DOI:10.1146/annurev.immunol.26.021607.090316] [PMID]
14. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA. 2000;97(21):11439-44. [DOI:10.1073/pnas.200360997] [PMID] [PMCID]
15. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408(6808):57-63. [DOI:10.1038/35040504] [PMID]
16. Davis ID, Skrumsager BK, Cebon J, Nicholaou T, Barlow JW, Moller NP, et al. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007;13(12):3630-6. [DOI:10.1158/1078-0432.CCR-07-0410] [PMID]
17. Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448(7152):484-487. [DOI:10.1038/nature05970] [PMID] [PMCID]
18. Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157(5):683-94. [DOI:10.1176/appi.ajp.157.5.683] [PMID]
19. Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N, Lukic ML. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res. 2012;46(11):1421-6. [DOI:10.1016/j.jpsychires.2012.08.016] [PMID]
20. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-41. [DOI:10.1038/ni1261] [PMID] [PMCID]
21. Sarkar S, Tesmer LA, Hindnavis V, Endres JL, Fox DA. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum. 2007;56(1):89-100. [DOI:10.1002/art.22311] [PMID]
22. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014;13(5):379-95. [DOI:10.1038/nrd4296] [PMID]
23. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004;172(4):2048-58. [DOI:10.4049/jimmunol.172.4.2048] [PMID]
24. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448(7152):480-3. [DOI:10.1038/nature05969] [PMID]
25. Al-Fahad D, Majeed K, Al-Naqshbandi A, Al-Amery A, Fahad Alharbi B. The Cytokines Responses against Parvovirus B19 in Miscarriage Women and the Susceptibility of their RhD Blood Type to Contract Parvovirus B19 in South of Iraq. Rep Biochem Mol Biol. 2021;10(3):462-470. [DOI:10.52547/rbmb.10.3.462] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
